^
    Back
    Association details:
    Biomarker:AR overexpression
    Cancer:Prostate Cancer
    Drug:Xtandi (enzalutamide) (Androgen receptor inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    Eur Urol
    Title:

    Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer

    Excerpt:
    Pretreatment tumor nuclear AR overexpression (>75%) and CYP17 (>10%) expression were associated with benefit (p = 0.018).
    DOI:
    10.1016/j.eururo.2014.05.005
    Trial ID:
    NCT01091103